AR025135A1 - A PHARMACEUTICAL COMPOSITION, THE USE OF A NON-PEPTIDIC CYSTINE DERIVATIVE, AND NEW NON-PEPTIDIC CYSTINE DERIVATIVES - Google Patents

A PHARMACEUTICAL COMPOSITION, THE USE OF A NON-PEPTIDIC CYSTINE DERIVATIVE, AND NEW NON-PEPTIDIC CYSTINE DERIVATIVES

Info

Publication number
AR025135A1
AR025135A1 ARP990105639A ARP990105639A AR025135A1 AR 025135 A1 AR025135 A1 AR 025135A1 AR P990105639 A ARP990105639 A AR P990105639A AR P990105639 A ARP990105639 A AR P990105639A AR 025135 A1 AR025135 A1 AR 025135A1
Authority
AR
Argentina
Prior art keywords
peptidic
cystine
carbocyclic ring
aromatic
benzyloxycarbonyl
Prior art date
Application number
ARP990105639A
Other languages
Spanish (es)
Original Assignee
Roche Olivier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Olivier filed Critical Roche Olivier
Publication of AR025135A1 publication Critical patent/AR025135A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones farmacéuticas que contienen derivados de cistina no peptídicos, de la formula general (1): en la cual R1 y R3 pueden ser iguales o diferentesy se seleccionan entre hidrogeno, un anillo heterocíclico o carbocíclico aromático o no aromático, o un grupo alquilo saturado o insaturado, lineal oramificado C1-15, que puede interrumpirse mediante un heteroátomo y que puede sustituirse a través de un anillo heterocíclico o carbocíclico aromático ono aromático. R2 y R4 pueden ser iguales o diferentes y se seleccionan entre hidrogeno, un grupo alquilo saturado o insaturado, lineal o mramificado, de 1 a 15átomos de carbono, que puede interrumpirse mediante un heteroátomo y que puede sustituirse a través de un anillo heterocíclico o carbocíclico aromático o noaromático, y A es un enlace de valencia o un grupo -CO-, SO2-, -NHCO-, NHCS- u -O-CO-, sus sales farmacologicamente aceptables y las formas opticamente activasde los mismos y los portadores farmacéuticamente aceptables, para el tratamiento de las enfermedades seleccionadas entre sí: el crecimiento tumoral y lametástasis, las enfermedades inflamatorias, como la osteoartritirs y artritis reumatoide, osteoporosis, esclerosis multiple, periodontitis, restenosis,enfermedades causadas por bacterias, tales como la meningitis, el envejecimiento de la piel inducido por el sol y el mal de Alzheimer, y nuevos compuestos dela formula general (1) en la cual R1, R2, R3 R4 y A tienen los valores dados anteriormente pero con la condicion de que si R2 y R4 son bencilo, R1-A y R3-A nopueden ser formilo, alquilcarbonilo C1-10, benzoilo, toluensulfonilo o benciloxicarbonilo, y si R1-A y R3-A son benciloxicarbonilo, R2 y R4 no pueden serpiridilmetilo, feniletilo, 4-hidroxifeniletilo, 4-clorofenilmetil, fenilpropilo o indoliletilo, sus sales farmacologicameante aceptables y las formasopticamente activas de los mismos.Pharmaceutical compositions containing non-peptide cystine derivatives of the general formula (1): in which R1 and R3 may be the same or different and are selected from hydrogen, an aromatic or non-aromatic heterocyclic or carbocyclic ring, or a saturated alkyl group or unsaturated, linear or C1-15 branched, which can be interrupted by a heteroatom and which can be substituted by an aromatic heterocyclic or carbocyclic ring. R2 and R4 can be the same or different and are selected from hydrogen, a saturated or unsaturated, linear or branched alkyl group, from 1 to 15 carbon atoms, which can be interrupted by a heteroatom and which can be substituted through a heterocyclic or carbocyclic ring aromatic or noaromatic, and A is a valence bond or a group -CO-, SO2-, -NHCO-, NHCS- or -O-CO-, its pharmacologically acceptable salts and optically active forms thereof and pharmaceutically acceptable carriers , for the treatment of diseases selected from each other: tumor growth and metastasis, inflammatory diseases, such as osteoarthrites and rheumatoid arthritis, osteoporosis, multiple sclerosis, periodontitis, restenosis, diseases caused by bacteria, such as meningitis, aging of sun-induced skin and Alzheimer's disease, and new compounds of the general formula (1) in which R1, R2, R3 R4 and A have the values given above but with the proviso that if R2 and R4 are benzyl, R1-A and R3-A cannot be formyl, C1-10 alkylcarbonyl, benzoyl, toluenesulfonyl or benzyloxycarbonyl, and if R1-A and R3-A are benzyloxycarbonyl, R2 and R4 cannot be pyridylmethyl, phenylethyl, 4-hydroxyphenylethyl, 4-chlorophenylmethyl, phenylpropyl or indolylethyl, their pharmacologically acceptable salts and the optically active forms thereof.

ARP990105639A 1998-11-06 1999-11-08 A PHARMACEUTICAL COMPOSITION, THE USE OF A NON-PEPTIDIC CYSTINE DERIVATIVE, AND NEW NON-PEPTIDIC CYSTINE DERIVATIVES AR025135A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98121073 1998-11-06

Publications (1)

Publication Number Publication Date
AR025135A1 true AR025135A1 (en) 2002-11-13

Family

ID=8232930

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105639A AR025135A1 (en) 1998-11-06 1999-11-08 A PHARMACEUTICAL COMPOSITION, THE USE OF A NON-PEPTIDIC CYSTINE DERIVATIVE, AND NEW NON-PEPTIDIC CYSTINE DERIVATIVES

Country Status (11)

Country Link
EP (1) EP1143960A2 (en)
JP (1) JP2002529404A (en)
KR (1) KR20010100983A (en)
CN (1) CN1346272A (en)
AR (1) AR025135A1 (en)
AU (1) AU1379600A (en)
BR (1) BR9915127A (en)
CA (1) CA2348946A1 (en)
TR (1) TR200101222T2 (en)
WO (1) WO2000027378A2 (en)
ZA (1) ZA200103605B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101332157B (en) 1998-10-09 2012-01-11 味之素株式会社 Cysteine derivatives
JP2002226457A (en) * 2001-02-02 2002-08-14 Ajinomoto Co Inc New cystine derivative and inflammation factor activation inhibitor
EP1871420A4 (en) 2005-04-15 2010-09-22 Univ North Carolina Methods of facilitating cell survival using neurotrophin mimetics
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
EP3470402B1 (en) 2009-11-12 2021-01-06 Pharmatrophix Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
JP6838743B2 (en) * 2015-06-08 2021-03-03 公立大学法人大阪 Non-peptide GAPDH aggregation inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1478002A (en) * 1975-02-12 1977-06-29 Ecnpk Biolog I Mediko Biolog P Pharmaceutical composition having anti-tumour activity

Also Published As

Publication number Publication date
EP1143960A2 (en) 2001-10-17
ZA200103605B (en) 2001-12-11
TR200101222T2 (en) 2001-12-21
BR9915127A (en) 2001-07-31
CN1346272A (en) 2002-04-24
JP2002529404A (en) 2002-09-10
WO2000027378A3 (en) 2001-09-20
WO2000027378A2 (en) 2000-05-18
CA2348946A1 (en) 2000-05-18
AU1379600A (en) 2000-05-29
KR20010100983A (en) 2001-11-14

Similar Documents

Publication Publication Date Title
AR016523A1 (en) INDOL COMPOUNDS AS ANTI-INFLAMMATORY / ANALGESIC AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND TREATMENT PROCEDURE
EE200100487A (en) Novel Compounds and Compositions as Protease Inhibitors
PE20010130A1 (en) DERIVATIVES OF 3 (5) -AMINO-PIRAZOLE AND PROCEDURE FOR THEIR PREPARATION
GT200000005A (en) USEFUL REPLACED BICYCLE DERIVATIVES AS AGENTS AGAINST CANCER.
AR021949A1 (en) A TOPIC COMPOSITIONS, ITS USE, AND, A COSMETIC METHOD THAT USES IT.
PE20000339A1 (en) BICYCLE [2.2.1] HEPTANS AND RELATED COMPOUNDS
PT1075258E (en) NEW FATAL ANALOGS FOR THE TREATMENT OF OBESITY
CO4770945A1 (en) ANTI-PLAQUE ORAL COMPOSITIONS CONTAINING ALKYLATED PHENOL- ANTIBACTERIAL
ATE103812T1 (en) COMPOSITION FOR THE TREATMENT OF ISCHEMIC DISORDERS IN ORGANS.
ES2179353T3 (en) MUSCARINIC ANTAGONISTS.
SE0102055D0 (en) New Compounds
PE29798A1 (en) ACETIDINS
AR025135A1 (en) A PHARMACEUTICAL COMPOSITION, THE USE OF A NON-PEPTIDIC CYSTINE DERIVATIVE, AND NEW NON-PEPTIDIC CYSTINE DERIVATIVES
DK1063886T3 (en) Disinfectant
ES2143181T3 (en) BICYCLE DERIVATIVES OF ISOTIOUREA USEFUL IN THERAPY.
AR012323A1 (en) USE OF ALCOXYLATED STERESAMINE COMPOUNDS OR OF QUATERNIZED OR PROTONIZED FORMS OR MIXTURES THEREOF IN STABLE, SOFTENING, DETERGENT, CLEANING OR PERSONAL HYGIENE FORMULATIONS AND PROCEDURE FOR PREPARING APPLICATION COMPOSITIONS
AR023369A1 (en) SECRETAGOGOS OF THE HORMONE OF GROWTH
ATE337023T1 (en) CONTACT LENS CARE FOR HARD AND SOFT CONTACT LENSES
ES2058264T3 (en) SULFONILDECAHIDRO-8H-ISOQUINO (2,1-G) (1,6) NAFTIRIDINAS, OPTICAL ISOMERS OF THE SAME AND RELATED COMPOUNDS.
DE60007289T2 (en) USE OF MANZAMINES AS ANTI-INFLAMMATORY AGENTS
MX9307309A (en) DERIVATIVES OF PIRROLO, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS.
AR008107A1 (en) A COMPOUND OF THE ARIL 2,4-DIOX OXAZOLIDINE FAMILY, ITS USE, PROCEDURE FOR ITS PREPARATION, COSMETIC AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND A COSMETIC TREATMENT PROCEDURE
MX9303966A (en) DERIVATIVES OF BENZOTIAZEPINE AND BENZOXAZEPINE.
UY28618A1 (en) NEW SUBSTITUTED INDEPENDES OF PIPERIDINE OR HERERODERIVED OF THE SAME
AR029004A1 (en) ACID COMPOUND 7-ACILAMINO-3-HETEROARILTIO-3-CEBOEM CARBOXILICO AND ITS USE FOR THE PREPARATION OF AN ANTIBACTERIAL COMPOSITION